KINTOR PHARMA-B (09939) announced that the company's board has been notified by Dr. Tong Youzhi, the Chairman, Executive Director, and Chief Executive Officer, of his share purchases. Between April 2, 2026, and May 28, 2026, through his wholly-owned company KT International Investment Limited, Dr. Tong acquired approximately 1.2625 million shares of the company in the open market using his own funds. The total consideration was about HK$3.32 million, with an average price of HK$2.63 per share, within a price range of HK$2.23 to HK$2.89 per share.

Additionally, Dr. Tong exercised rights attached to 1.25 million restricted stock units granted under the company's 2020 Employee Incentive Plan at a cost of approximately HK$1.09 million. These shares vested on March 31, 2026.

In total, Dr. Tong increased his holdings by 2.5125 million shares, representing approximately 0.5039% of the company's total issued share capital as of the date of this announcement. Based on publicly available information and to the knowledge of the board, the company continues to maintain sufficient public float following these transactions.

Dr. Tong expressed his full confidence in the overall development prospects and commercial transformation of the group. He indicated that, subject to compliance with applicable laws and regulations, he does not rule out the possibility of further increasing his shareholdings in the company in the future.

The board believes that these share purchases demonstrate Dr. Tong's firm confidence in the clinical progress and commercial prospects of the company's external innovative drugs, particularly its pipeline for hair loss prevention and regrowth, as well as its growth potential. It also reflects his full recognition of the company's long-term investment value.